Page 2 - Five Prime News Today

Apexigen Announces Appointment of Francis Sarena as Chief Operating Officer - read this article along with other careers information, tips and advice on BioSpace

A physician and professor at the University of Chicago entered a plea of not guilty Tuesday to charges that he traded on inside information from Five Prime Therapeutics Inc. ahead of the publication of positive results of a drug trial for its leading cancer drug bemarituzumab.

Dr Daniel Catenacci, the lead investigator in a clinical trial for the drug bemarituzumab, has been charged with violating the antifraud provisions of the federal securities laws.

A physician and professor at the University of Chicago has been accused of trading on inside information from Five Prime Therapeutics Inc. ahead of the publication of positive results of a drug trial for its leading cancer drug bemarituzumab, prosecutors said Monday.

<p><span>The Securities and Exchange Commission today announced charges against Daniel V.T. Catenacci for insider trading in the securities of biotechnology company Five Prime Therapeutics, Inc. in advance of the company’s November 10, 2020 announcement that it had achieved positive drug trial results for its flagship cancer drug Bemarituzumab.</span></p>

Amgen today announced financial results for the third quarter of 2021. Key results include: Total revenues increased 4% to $6.7 billion in comparison to the third quarter of 2020, driven by higher unit demand, partially offset by lower net selling prices. Product sales increased 4% globally, driven by double-digit volume growth across a number of our products, including Prolia ® EVENITY ® Repatha ® and MVASI ® . ...

Amgen Reports Second Quarter 2021 Financial Results Amgen today announced financial results for the second quarter of 2021. Key results include: Total revenues increased 5% to $6.5 billion in comparison to the second quarter of 2020, driven by higher unit demand, partially offset by lower net selling prices. Product sales increased 3% globally, driven by double digit volume growth across a number of our products including Prolia ® Repatha ® and our biosimilar … – Amgen (NASDAQ:AMGN) toda...

TOP NEWS SUMMARY: Strong PMIs in Europe but Australia suffers setback Wed, 4th Aug 2021 10:50 (Alliance News) - The following is a summary of top news stories Wednesday. COMPANIES Spains top football league said it has agreed in principle to sell 10% of its business to private equity firm CVC Capital Partners for EUR2.7 billion to help finance its long-term growth plans. The deal for the ownership stake, the first of its type by a major European league, values La Liga at around EUR24.2 billion,...

Amgen today announced updated results for investigational bemarituzumab in combination with chemotherapy from the Phase 2 FIGHT trial. The trial evaluated bemarituzumab plus chemotherapy versus chemotherapy alone in patients with FGFR2b-positive, HER2-negative frontline advanced gastric or gastroesophageal junction cancers . New data includes median overall survival a secondary endpoint that was reached with longer ...

When you have to grow your own nest egg, a balance among growth, reliability, and longevity must be found.